PRODUCT	CODE	QTY	USD
Resins			
o-BAL-CLEAR Resin *ortho*-Backbone Amide Linker attached to CLEAR *Resin for the synthesis of C-terminally Modified Peptides (peptide acids, esters, aldehydes, alcohols, head-to-tail cyclic peptides)*	CBL-1291-PI 4 °C	*Please Inquire*	
p-BAL-CLEAR Resin *para*-Backbone Amide Linker attached to CLEAR *Resin for the synthesis of C-terminally Modified Peptides (peptide acids, esters, aldehydes, alcohols, head-to-tail cyclic peptides)*	CBL-1292-PI 4 °C	*Please Inquire*	
Fmoc-D-Lys(Boc)-CLEAR-Acid Resin (100-200 mesh) 1% DVB	CFK-1273-PI 4 °C	1 g 5 g	120 435
Fmoc-D-Ala-Wang Resin (100-200 mesh) 1% DVB	RFA-1356-PI 4 °C	1 g 5 g	60 240
Fmoc-D-Arg(Pbf)-Wang Resin (100-200 mesh) 1% DVB	RFR-1347-PI 4 °C	1 g 5 g	60 240
Fmoc-D-Leu-Wang Resin (100-200 mesh) 1% DVB	RFL-1357-PI 4 °C	1 g 5 g	60 240
H-Asn-2-Cltrt-Resin (100-200 mesh) 1% DVB	RHN-11052-PI 4 °C	1 g 5 g	30 115
H-Gln-2-Cltrt-Resin (100-200 mesh) 1% DVB	RHQ-11057-PI 4 °C	1 g 5 g	30 115
H-mini-PEG-2-ClTrt-Resin (100-200 mesh) 1% DVB mini-PEG™ = 8-Amino-3,6-Dioxaoctanoic Acid	RHX-11074-PI 4 °C	1 g 5 g	99 396
TentaGel S PHB-Gly-Fmoc Resin (90 µm)	RTS-9950-PI 4 °C	1 g 5 g	59 214
TentaGel S PHB-Leu-Fmoc Resin (90 µm)	RTS-9951-PI 4 °C	1 g 5 g	59 214
Boc-Lys-(Fmoc)-O-Resin (100-200 mesh) 1% DVB	RBK-1139-PI 4 °C	1 g 5 g	75 275
Reagents			
o-BAL **5-(2-Formyl-3,5-Dimethoxyphenoxy)Pentanoic Acid** *ortho*-Backbone Amide Linker (M.W. 282.30) $C_{14}H_{18}O_6$ *Handle for the Synthesis of C-terminally Modified Peptides (peptide acids, esters, aldehydes, alcohols, head-to-tail cyclic peptides)*	KBL-1002-PI -20 °C	5 g 25 g	235 940
p-BAL **5-(4-Formyl-3,5-Dimethoxyphenoxy)Pentanoic Acid** *para*-Backbone Amide Linker (M.W. 282.30) $C_{14}H_{18}O_6$ *Handle for the Synthesis of C-terminally Modified Peptides (peptide acids, esters, aldehydes, alcohols, head-to-tail cyclic peptides)*	KBL-1006-PI -20 °C	5 g 25 g	235 940
Biologically Active Peptides			
Arg-Gly-Asp (RGD) Related Peptides			
DOTA-Glu-[*cyclo* (Arg-Gly-Asp-D-Phe-Lys)]$_2$ **DOTA-E-[c(RGDfK)$_2$]** (M.W. 1704.88) $C_{75}H_{113}N_{23}O_{23}$ *$\alpha_v\beta_3$ Integrin Binding RGD Peptide RGD Tumor Targeting Peptide for Radiolabelling* (Requires further derivatization before use) M.L. Janssen, W.J. Oyen, I. Dijkgraaf, L.F. Massuger, C. Frielink, D.S. Edwards, M. Rajopadhye, H. Boonstra, F.H. Corstens, and O.C. Boerman, *Cancer Res.*, **62**, 6146 (2002). X. Chen, S. Liu, Y. Hou, M. Tohme, R. Park, J.R. Bading, and P.S. Conti, *Mol. Imaging Biol.*, **6,** 350 (2004).	PCI-3903-PI -20 °C	1 mg 5 mg	89 345
H-Glu[*cyclo* (Arg-Gly-Asp-D-Phe-Lys)]$_2$ **H-E[c(RGDfK)]$_2$** Trifluoroacetate Salt (M.W. 1318.47) $C_{59}H_{87}N_{19}O_{16}$ *RGD Tumor Targeting and Tumor Imaging Peptide* (Requires further derivatization before use).	PCI-3904-PI -20 °C	1 mg 5 mg 25 mg	69 225 795
H-Gly-Arg-Gly-Glu-Ser-OH *Fibronectin Active Fragment Negative Control*	PFA-3907-PI -20 °C	5 mg 25 mg	50 225

PRODUCT	CODE	QTY	USD
H-Gly-Arg-Ala-Asp-Ser-Pro-OH **GRADSP**	**PCI-3910-PI** -20 °C	1 mg 5 mg	45 175
H-Gly-Arg-Gly-Asp-Asn-Pro-OH **GRGDNP**	**PCI-3909-PI** -20 °C	5 mg 25 mg	75 295
H-Glu[*cyclo* (Arg-Gly-Asp-D-Tyr-Lys)]$_2$ **H-E[*c*(RGDyK)]$_2$** (M.W. 1350.47) $C_{59}H_{87}N_{19}O_{18}$ *RGD Tumor Targeting and Tumor Imaging Peptide* (Requires further derivatization before use)	**PCI-3899-PI** -20 °C	1 mg 5 mg 25 mg	69 225 795
Y. Wu, X. Zhang, Z. Xiong, Z. Cheng , D.R. Fisher, S. Liu, S.S. Gambhir, and X. Chen, *J. Nucl. Med.*, **46**, 1707 (2005). X. Chen, S. Liu, Y. Hou, M. Tohme, R. Park, J.R. Bading, and P.S. Conti, *Mol. Imaging Biol.*, **6**, 350 (2004). X. Chen, C. Plasencia, Y. Hou, and N. Neamati, *J. Med. Chem.*, **48**, 1098 (2005). X. Chen, M. Tohme, R. Park, Y. Hou, J.R. Bading, and P.S. Conti, *Mol. Imaging*, **3**, 96 (2004).			
***cyclo* (Arg-Ala-Asp-D-Tyr-Lys)** ***c*(RADyK)** (M.W. 633.71) $C_{28}H_{43}N_9O_8$ *Control Peptide of cyclo (Arg-Gly-Asp-D-Tyr-Lys) (PCI-3662-PI)*	**PCI-3894-PI** -20 °C	1 mg 5 mg 25 mg	49 149 595
***cyclo* [Arg-Gly-Asp-D-Phe-Lys(Biotin)]** ***c*[RGDfK(Biotin)]** Acetate Salt (M.W. 829.98) $C_{37}H_{55}N_{11}O_9S$ *$\alpha_v\beta_3$ Integrin Binding RGD Peptide RGD Tumor Targeting Peptide* (Requires further derivatization before use)	**PCI-3895-PI** -20 °C	1 mg 5 mg	59 175
***cyclo* [Arg-Gly-Asp-D-Phe-Lys(H-Ser)]** ***c*[RGDfK(H-Ser)]** (M.W. 690.76) $C_{30}H_{46}N_{10}O_9$ *$\alpha_v\beta_3$ Integrin Binding RGD Peptide RGD Tumor Targeting Peptide* (Requires further derivatization before use)	**PCI-3898-PI** -20 °C	1 mg 5 mg	59 175
Defensin Peptides			
α-Defensin-2 (Human) *Antimicrobial Peptide*	**PDF-4428-s** -20 °C	0.1 mg vial	212
Ghrelin Related Peptides			
[Trp^3, Arg^5]-Ghrelin (1-5) **GSWFR** H-Gly-Ser-Trp-Phe-Arg-OH (M.W. 651.73) $C_{31}H_{41}N_9O_7$ *Growth-Hormone Secretagogue (GHS) Receptor Agonist / Stimulates Food-Intake*	**PGH-3902-PI** -20 °C	1 mg 5 mg	35 95
K. Ohinata, K. Kobayashi, M. Yoshikawa, *Peptides*, **27**, 1632 (2006).			
Des-Acyl Ghrelin (Human) **Des-*n*-Octanoyl Ghrelin (Human)** Trifluoroacetate Salt Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg (M.W. 3244.7) $C_{141}H_{235}N_{47}O_{41}$ *Des-Octanoylated Ghrelin with Distinct Effect on Food Intake*	**PGH-4436-s** -20 °C	0.1 mg vial	115
• This compound is distributed through Peptide Institute, Inc. under the license of Dr. K. Kangawa.			
Des-Acyl Ghrelin (Rat) **Des-*n*-Octanoyl Ghrelin (Rat)** Trifluoroacetate salt Gly-Ser-Ser-Phe-Leu-Ser-Pro-Glu-His-Gln-Lys-Ala-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg (M.W. 3188.6) $C_{139}H_{231}N_{45}O_{41}$ *Des-Octanoylated Ghrelin with Distinct Effect on Food Intake*	**PGH-4437-s** -20 °C	0.1 mg vial	115
• This compound is distributed through Peptide Institute, Inc. under the license of Dr. K. Kangawa.			
Guangxitoxin			
Guangxitoxin-1E *Kv2.1/Kv2.2 Channel Blocker / Enhancer of Glucose-Stimulated Insulin Secretion*	**PGX-4433-s** -20 °C	0.1 mg vial	229
J. Herrington, Y.-P. Zhou, R.M. Bugianesi, P.M. Dulski, Y. Feng, V.A. Warren, M.M. Smith, M.G. Kohler, V.M. Garsky, M. Sanchez, M. Wagner, K. Raphaelli, P. Banerjee, C. Ahaghotu, D. Wunderler, B.T. Priest, J.T. Mehl, M.L. Garcia, O.B. McManus, G.J. Kaczorowski, and R.S. Slaughter, *Diabetes*, **55**, 1034-1042 (2006).			

PRODUCT	CODE	QTY	USD
Liver-Expressed Antimicrobial Peptides			
Hepcidin (Mouse) *(Coming Soon)* Liver-Expressed Antimicrobial Peptide 1 (LEAP-1) (Mouse) *Iron-Regulatory Hormone*	**PLP-4434-s** -20 °C	0.1 mg	229
Melanotropins			
H-Tyr-Val-Met-Gly-His-Phe-Arg-D-Trp-Asp-Arg-Phe-Gly-OH **YVMGHFRwDRFG** (M.W. 1570.81) $C_{74}H_{99}N_{21}O_{16}S$ *Potent and Selective Melanocortin 3 (MC3) Receptor Agonist* D. Marks, V.J. Hruby, G. Brookhart, and R.D. Cone, *Peptides*, **27**, 259 (2006). P. Grieco, P.M. Balse, D. Weinberg, T. MacNeil, and V.J. Hruby, *J. Med. Chem.*, **43**, 4998 (2000).	**PMC-3897-PI** -20 °C	1 mg 5 mg	49 195
Muscarinic Toxins			
Muscarinic Toxin 3 **[MT3, MTX3, m4-toxin]** **(Green Mamba, *Dendroaspis angusticeps*)** Synthetic Product Leu-Thr-Cys-Val-Thr-Lys-Asn-Thr-Ile-Phe-Gly-Ile-Thr-Thr-Glu-Asn-Cys-Pro-Ala-Gly-Gln-Asn-Leu-Cys-Phe-Lys-Arg-Trp-His-Tyr-Val-Ile-Pro-Arg-Tyr-Thr-Glu-Ile-Thr-Arg-Gly-Cys-Ala-Ala-Thr-Cys-Pro-Ile-Pro-Glu-Asn-Tyr-Asp-Ser-Ile-His-Cys-Cys-Lys-Thr-Asp-Lys-Cys-Asn-Glu (Disulfide bonds between Cys^3- Cys^{24}, Cys^{17}- Cys^{42}, Cys^{46}- Cys^{57}, and Cys^{58}- Cys^{63}) (M.W. 7379.4) $C_{319}H_{489}N_{89}O_{97}S_8$ *Specific Ligand for Muscarinic Acetylcholine Receptor-4 (M_4)* M. Jolkkonen, P.L.M. van Giersbergen, U. Hellman, C. Wernstedt, and E. Karlsson, *FEBS Lett.*, **352**, 91 (1994). (Original; MT3) J.-S. Liang, J. Carsi-Gabrenas, J.L. Krajewski, J.M. McCafferty, S.L. Purkerson, M.P. Santiago, W.L. Strauss, H.H. Valentine, and L.T. Potter, *Toxicon*, **34**, 1257 (1996). (Original; m4-toxin) A. Adem and E. Karlsson, *Life Sci.*, **60**, 1069 (1997). (*Pharmacol.; Muscarinic Receptor Subtype Specificity*) S. Katayama, M. Ishimaru, H. Nishio, Y. Nishiuchi, and T. Kimura, *Peptide Science 2004*, 161 (2005). (S-S Bond)	**PMT-4410-s** -20 °C	0.1 mg vial	315
Muscarinic Toxin α *(Coming Soon)* **MTα** **(Black Mamba, *Dendroaspis polylepis*)** Leu-Thr-Cys-Val-Thr-Ser-Lys-Ser-Ile-Phe-Gly-Ile-Thr-Thr-Glu-Asn-Cys-Pro-Asp-Gly-Gln-Asn-Leu-Cys-Phe-Lys-Lys-Trp-Tyr-Tyr-Leu-Asn-His-Arg-Tyr-Ser-Asp-Ile-Thr-Trp-Gly-Cys-Ala-Ala-Thr-Cys-Pro-Lys-Pro-Thr-Asn-Val-Arg-Glu-Thr-Ile-His-Cys-Cys-Glu-Thr-Asp-Lys-Cys-Asn-Glu (Disulfide bonds between Cys^3-Cys^{24}, Cys^{17}-Cys^{42}, Cys^{46}-Cys^{58}, and Cys^{59}-Cys^{64}) (M.W. 7545.4) $C_{326}H_{491}N_{89}O_{102}S_8$ *Ligand for Muscarinic Acetylcholine Receptor-3/5 (M3/M5) (Non-specific Ligand)* M. Jolkkonen, P.L.M. van Giersbergen, U. Hellman, C. Wernstedt, A. Oras, N. Satyapan, A. Adem, and E. Karlsson, *Eur. J. Biochem.*, **234**, 579 (1995). (*Original; MTα*) A. Adem and E. Karlsson, *Life Sci.*, **60**, 1069 (1997). (*Pharmacol.; Muscarinic Receptor Subtype Specificity*) M. Jolkkonen, A. Oras, T. Toomela, E. Karlsson, J. Järv, and K.E.O. Åkerman, *Toxicon*, **39**, 377 (2001). (*Pharmacol.; Mechanism of Receptor Binding*)	**PMT-4424-s** -20 °C	0.1 mg vial	315
Neuromedins			
Neuromedin U (Porcine, 1-8) H-Tyr-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH_2 (M.W. 1111.32) $C_{54}H_{78}N_{16}O_{10}$ *Neuropeptide*	**PNM-3698-PI** -20 °C	1 mg 5 mg	35 139
Neuromedin S (Human) **NMS (Human)** Ile-Leu-Gln-Arg-Gly-Ser-Gly-Thr-Ala-Ala-Val-Asp-Phe-Thr-Lys-Lys-Asp-His-Thr-Ala-Thr-Trp-Gly-Arg-Pro-Phe-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH_2 (M.W. 3791.3) $C_{173}H_{265}N_{53}O_{44}$ *Food Intake Suppressor / Regulator of Circadian Rhythm* K. Mori, M. Miyazato, T. Ida, N. Murakami, R. Serino, Y. Ueta, M. Kojima, and K. Kangawa, *EMBO J.*, **24**, 325 (2005). (*Original*) T. Ida, K. Mori, M. Miyazato, Y. Egi, S. Abe, K. Nakahara, M. Nishihara, K. Kangawa, and N. Murakami, *Endocrinology*, **146**, 4217 (2005). (*Pharmacol.; Anorexigenic Hormone*) • This compound is distributed through Peptide Institute, Inc. under the license of National Cardiovascular Center and Takeda Chemical Industries, Ltd.	**PNM-4426-s** -20 °C	1 mg vial	116

PRODUCT	CODE	QTY	USD

Neuromedin S (Rat)

NMS (Rat)

Leu-Pro-Arg-Leu-Leu-His-Thr-Asp-Ser-Arg-Met-Ala-Thr-Ile-Asp-Phe-Pro-Lys-Lys-Asp-Pro-Thr-Thr-Ser-Leu-Gly-Arg-Pro-Phe-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH_2

(M.W. 4241.9) $C_{193}H_{307}N_{57}O_{49}S$

Food Intake Suppressor / Regulator of Circadian Rhythm

PNM-4427-s -20 °C	0.1 mg vial	126

K. Mori, M. Miyazato, T. Ida, N. Murakami, R. Serino, Y. Ueta, M. Kojima, and K. Kangawa, *EMBO J.*, **24**, 325 (2005). (*Original*)
T. Ida, K. Mori, M. Miyazato, Y. Egi, S. Abe, K. Nakahara, M. Nishihara, K. Kangawa, and N. Murakami, *Endocrinology*, **146**, 4217 (2005). (*Pharmacol.; Anorexigenic Hormone*)

• This compound is distributed through Peptide Institute, Inc. under the license of National Cardiovascular Center and Takeda Chemical Industries, Ltd.

Obestatins

Obestatin (Human)

Phe-Asn-Ala-Pro-Phe-Asp-Val-Gly-Ile-Lys-Leu-Ser-Gly-Val-Gln-Tyr-Gln-Gln-His-Ser-Gln-Ala-Leu-NH_2

(M.W. 2546.8) $C_{116}H_{176}N_{32}O_{33}$

Food Intake Suppressor / Ligand for GPR39

PGH-4429-s -20 °C	0.1 mg vial	69

J.V. Zhang, P.-G. Ren, O. Avsian-Kretchmer, C.-W. Luo, R. Rauch, C. Klein, and A.J.W. Hsueh, *Science*, **310**, 996 (2005). (*Original; Structure & Pharmacol.*)

Obestatin (Rat, Mouse)

Phe-Asn-Ala-Pro-Phe-Asp-Val-Gly-Ile-Lys-Leu-Ser-Gly-Ala-Gln-Tyr-Gln-Gln-His-Gly-Arg-Ala-Leu-NH_2

(M.W. 2516.8) $C_{114}H_{174}N_{34}O_{31}$

Food Intake Suppressor / Ligand for GPR39

PGH-4430-s -20 °C	0.1 mg vial	69

J.V. Zhang, P.-G. Ren, O. Avsian-Kretchmer, C.-W. Luo, R. Rauch, C. Klein, and A.J.W. Hsueh, *Science*, **310**, 996 (2005). (*Original; Structure & Pharmacol.*)

PAR Peptides

H-Val-Lys-Gly-Ile-Leu-Ser-NH_2

VKGILS-Amide

M.W. 614.79 $C_{28}H_{54}N_8O_7$

Protease-Activated Receptor 2 (PAR_2) Negative Control Peptide of PAR-3889-PI

PAR-3896-PI -20 °C	1 mg 5 mg	35 139

S.K. Bohm, W. Kong, D. Bromme, S.P. Smeekens, D.C. Anderson, A. Connolly, M. Kahn, H.A. Nelken,S.R. Coughlin, D.G. Payan, and N.W. Bunnett, *Biochem. J.*, **314**, 1009 (1996).

H-Tyr-Arg-Leu-Leu-Ser-Phe-NH_2

YRLLSF-Amide

(M.W. 796.46) $C_{39}H_{60}N_{10}O_8$

Protease-Activated Receptor 2 (PAR_2) Negative Control Peptide of PAR-3888-PI

PAR-3906-PI -20 °C	1 mg 5 mg	35 139

Plectasin

Plectasin *(Coming Soon)*

Antimicrobial Peptide

PDF-4432-s -20 °C	0.1 mg vial	239

ProTx-I

ProTx-1

(Tarantula, *Thrixopelma pruriens*)

Glu-Cys-Arg-Tyr-Trp-Leu-Gly-Gly-Cys-Ser-Ala-Gly-Gln-Thr-Cys-Cys-Lys-His-Leu-Val-Cys-Ser-Arg-Arg-His-Gly-Trp-Cys-Val-Trp-Asp-Gly-Thr-Phe-Ser

(Disulfide bonds between Cys^2-Cys^{16}, Cys^9-Cys^{21}, and Cys^{15}-Cys^{28})

(M.W. 3987.5) $C_{171}H_{245}N_{53}O_{47}S_6$

T-Type Ca^{2+} Channel / Na^+ Channel / K^+ Channel Blocker (Gating Modifier)

PTX-4409-s -20 °C	0.1 mg vial	232

R.E. Middleton, V.A. Warren, R.L. Kraus, J.C. Hwang, C.J. Liu, G. Dai, R.M. Brochu, M.G. Kohler, Y.-D. Gao, V.M. Garsky, M.J. Bogusky, J.T. Mehl, C.J. Cohen, and M.M. Smith, *Biochemistry*, **41**, 14734 (2002). (*Original*)

Psalmotoxin 1

Psalmotoxin 1 *(Coming Soon)*

Selective Blocker for Acid-Sensitive Ion Channel, ASIC1a

PTX-4435-s -20 °C	0.1 mg vial	245

RGD Peptides – See Arg-Gly-Asp Related Peptides

Substrates

Abz-Ala-Gly-Leu-Ala-*p*-Nitro-Benzyl-Amide

Trifluoroacetate Salt

2-Aminobenzoyl-L-Alanyl-Glycyl-L-Leucyl-L-Alanyl-*para*-Nitro-Benzyl-Amide

(M.W. 583.65) $C_{28}H_{37}N_7O_7$

Substrate for Thermolysin and Neutral Endopeptidase 24.11 (NEP)

SAG-3905-PI -20 °C	5 mg 25 mg	45 175

N. Nishino and J.C. Powers, *J. Biol. Chem.*, **255**, 3482 (1980).
R.S. Rush, M. Mitas, J.C. Powers, T. Tanaka, and L.B. Hersh, *Arch. Biochem. Biophys*, **231**, 390 (1984).
D.I. Mundy and W.J. Strittmatter, *Cell* , **40**, 645 (1985)

PRODUCT	CODE	QTY	USD

Inhibitors

Z-Val-Ala-Asp(OMe)-CH_2F

ICA-3188-v -20 °C — 1 mg vial — 109

[Z-VAD-FMK]
{Benzyloxycarbonyl-L-Valyl-L-Alanyl-[(2*S*)-2-Amino-3-(Methoxycarbonyl)propionyl]}
Fluoromethane
(M.W. 467.49) $C_{22}H_{30}N_3O_7F$
Synthetic Product
Inhibitor for Caspases

E.A. Slee, H. Zhu, S.C. Chow, M. MacFarlane, D.W. Nicholson, and G.M. Cohen, *Biochem. J.*, **315**, 21 (1996).
H. Zhu, H.O. Fearnhead, and G.M. Cohen, *FEBS Lett.*, **374**, 303 (1995)

Pepstatin A (Purity Higher than 90% by HPLC)

IPA-4397 -20 °C — 25 mg — 75; 100 mg — 178

Microbial Product

In 2003, we began distributing Pepstatin A of "purity higher than 90%" when analyzed by RP-HPLC (code IPA-4397). This new item was welcomed by a majority of our customers. However, this accompanied some complaints because of its low solubility. At the beginning, we thought this low solubility was the destiny of the higher purity Pepstatin A. In striving to offer our customers satisfactory service, we continued to improve the solubility of this item. Recently, we have succeeded in obtaining both higher purity and higher solubility Pepstatin A. This new improved Pepstatin A is now available from us with easier handling.

Carbohydrates & Conjugates

Antiproliferative Factor Sialoglycopeptide *(see page 221)*

CAR-24007-v -20 °C — 50 µg vial — 212

Antiproliferative Factor from Interstitial Cystitis Patients

Peptide Antisera

Adrenomedullin 2 (Human, 1-7) Antiserum (Rabbit)

NAD-14438-v -20 °C — 50 µL vial — 339

Antiserum: lyophilized from 0.001M Phosphate Buffer (pH 7.0)
Immunogen: Adrenomedullin 2 (Human, 1-7)-TG}
(TG: Bovine Thyroglobulin)

Reactivity:		
	Adrenomedullin 2 (Human)	+
	Adrenomedullin (Human)	-
	Calcitonin (Human)	-
	CGRP (Human)	-

Salusin-β (Human) Antiserum (Rabbit)

NLS-14418-v -20 °C — 50 µL vial — 339

Antiserum: lyophilized from 0.001M Phosphate Buffer (pH 7.0)
Immunogen: Salusin β (Human7)-TG
(TG: Bovine Thyroglobulin)

Reactivity:		
	Salusin β (Human)	+
	Salusin α (Human)	-